MAGNESIUM METALLICUM
Cytomegalovirus Infections
Small moleculePhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Cytomegalovirus Infections cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ganciclovir City of Hope Medical Center | Phase 3 | BB |
Sdz Msl-109 National Center for Research Resources (NCRR) | Phase 1/2 | CCC |
Adenovirus Specific T- Lymphocytes Jessie L. Alexander | Phase 1/2 | CCC |
Epstein-Barr Virus Specific T-Lymphocytes Jessie L. Alexander | Phase 1/2 | CCC |
Cytomegalovirus -Specific Cytotoxic T Cells Jessie L. Alexander | Phase 1/2 | CC |
View all 9 →
Same molecule, other indications
MAGNESIUM METALLICUM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →